From 2001 to 2006, the incidence of hepatocellular carcinoma (HCC) increased significantly with an average increase of 3.5% annually. This analysis was recently reported in the Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality... Continue Reading
Women with Hypothyroidism at Increased Risk of Liver Cancer (June 22, 2009)Women with Hypothyroidism at Increased Risk of Liver Cancer Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.[1] The liver... Continue Reading
Incidence of Liver Cancer on the Rise (April 8, 2009)The incidence of liver cancer in the United States tripled between 1975 and 2005, but survival rates are improving, according to the results of a study published in the Journal of Clinical Oncology. The liver is the largest organ in the body and is responsible... Continue Reading
In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading
Women with Hypothyroidism at Increased Risk of Liver Cancer (June 22, 2009)Women with Hypothyroidism at Increased Risk of Liver Cancer Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.[1] The liver... Continue Reading
Genetic Characteristics of Hepatitis B Associated with Risk of Liver Cancer (March 8, 2009)Genetic Characteristics of Hepatitis B Associated with Risk of Liver Cancer Different genetic characteristics of the hepatitis B virus (HBV) are associated with varying risks of developing hepatocellular carcinoma (HCC), the most common form of liver... Continue Reading
Nexavar® Improves Survival in Advanced Liver Cancer (March 8, 2009)Nexavar® Improves Survival in Advanced Liver Cancer The targeted agent Nexavar (sorafenib) is associated with improved survival and doubling of the time to cancer progression for patients with advanced liver cancer. These results were recently published... Continue Reading
Liver Cancer Screening in Patients with Chronic Hepatitis B and C Improves Survival (March 8, 2009)Liver Cancer Screening in Patients with Chronic Hepatitis B and C Improves Survival Researchers in Hong Kong have reported that screening patients with chronic hepatitis for liver cancer improves liver cancer survival rates and may improve chances for... Continue Reading
More Hepatocellular Carcinoma Liver CancerSorry, there are no articles available for this cancer stage.
More Recurrent Liver CancerFrom 2001 to 2006, the incidence of hepatocellular carcinoma (HCC) increased significantly with an average increase of 3.5% annually. This analysis was recently reported in the Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality... Continue Reading
Women with Hypothyroidism at Increased Risk of Liver Cancer (June 22, 2009)Women with Hypothyroidism at Increased Risk of Liver Cancer Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.[1] The liver... Continue Reading
Genetic Characteristics of Hepatitis B Associated with Risk of Liver Cancer (March 8, 2009)Genetic Characteristics of Hepatitis B Associated with Risk of Liver Cancer Different genetic characteristics of the hepatitis B virus (HBV) are associated with varying risks of developing hepatocellular carcinoma (HCC), the most common form of liver... Continue Reading
Liver Cancer Screening in Patients with Chronic Hepatitis B and C Improves Survival (March 8, 2009)Liver Cancer Screening in Patients with Chronic Hepatitis B and C Improves Survival Researchers in Hong Kong have reported that screening patients with chronic hepatitis for liver cancer improves liver cancer survival rates and may improve chances for... Continue Reading
Increased Risk of Liver Cancer for Patients with Cirrhosis Who Overexpress EGF (March 8, 2009)Increased Risk of Liver Cancer for Patients with Cirrhosis Who Overexpress EGF According to an article recently published in the Journal of the American Medical Association, patients with cirrhosis of the liver who overexpress epithelial growth factor... Continue Reading
More Screening/Prevention Liver CancerIn a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading
Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma (March 8, 2009)Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma According to the results of a Phase II clinical trial, the combination of two targeted therapies-Avastin® (bevacizumab) and Tarceva® (erlotinib)-has anticancer activity in patients... Continue Reading
Nexavar® Effective for Hepatocellular Carcinoma in Asians (March 8, 2009)Nexavar® Effective for Hepatocellular Carcinoma in Asians Researchers from 23 medical centers in Asia have reported that Nexavar® (sorafenib) is effective in patients with advanced hepatocellular carcinoma (liver cancer). The results of this study were... Continue Reading
More Stage IV Liver CancerIn a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading
Differences in IMRT Radiation Doses May Complicate Study Results in Liver Cancer (March 8, 2009)Differences in IMRT Radiation Doses May Complicate Study Results in Liver Cancer Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies... Continue Reading
Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma (March 8, 2009)Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma According to the results of a Phase II clinical trial, the combination of two targeted therapies-Avastin® (bevacizumab) and Tarceva® (erlotinib)-has anticancer activity in patients... Continue Reading
Nexavar® Effective for Hepatocellular Carcinoma in Asians (March 8, 2009)Nexavar® Effective for Hepatocellular Carcinoma in Asians Researchers from 23 medical centers in Asia have reported that Nexavar® (sorafenib) is effective in patients with advanced hepatocellular carcinoma (liver cancer). The results of this study were... Continue Reading
More Stages I-III Liver Cancer